Insider Selling: Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells 9,200 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 9,200 shares of the company’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total value of $98,808.00. Following the transaction, the insider now owns 320,647 shares of the company’s stock, valued at approximately $3,443,748.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Los Pinos Elisabet De also recently made the following trade(s):

• On Friday, October 18th, Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock. The stock was sold at an average price of $12.04, for a total value of $300,903.68.

Aura Biosciences Stock Down 2.5 %

Shares of Aura Biosciences stock opened at $10.71 on Wednesday. The firm has a market cap of $530.61 million, a price-to-earnings ratio of -5.76 and a beta of 0.37. The business has a fifty day simple moving average of $9.05 and a 200-day simple moving average of $8.23. Aura Biosciences, Inc. has a fifty-two week low of $5.99 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.04. Analysts anticipate that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Institutional Trading of Aura Biosciences

Several institutional investors have recently modified their holdings of the company. Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the period. Regency Capital Management Inc. DE lifted its holdings in shares of Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock valued at $6,163,000 after buying an additional 80,162 shares during the period. Levin Capital Strategies L.P. lifted its holdings in shares of Aura Biosciences by 194.5% in the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after buying an additional 41,711 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after purchasing an additional 48,549 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on AURA shares. Scotiabank upped their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. HC Wainwright increased their price target on Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Finally, BTIG Research increased their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Aura Biosciences currently has an average rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.